ArticleBMC microbiology2025
Expression and application of a novel Holin Hol6A3 in phage PD6A3 of Acinetobacter baumannii.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overcoming prokaryotic toxicity: a SUMO-fused secretory platform in Komagataella phaffii for high-yield production of phage holin Hol41.Microbial cell factories · 2026Article
- Phage as control strategy against the foodborne pathogen, Bacillus cereus.Archives of microbiology · 2026Review
- Identification and Characterization of Holin-like Protein ORF70 from Cyanophage MaMV-DC.Marine drugs · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe current overuse of antibiotics presents significant challenges in treating drug-resistant bacterial infections. Bacteriophages have recently emerged as potential alternatives to antibiotics. Nevertheless, their high specificity and narrow host range limit their clinical application.
methodsThe entire genome of phage PD6A3 was sequenced. Bioinformatic tools were employed to predict genes and determine protein structures. A prokaryotic expression system for Hol6A3 was established. The antibacterial efficacy, thermal and pH stability, and cytotoxicity of Hol6A3 were thoroughly investigated. Additionally, the in vitro antibacterial application of Holin was also studied.
resultsThis study achieved high-purity expression of Hol6A3, with a purity of 1.47 mg/ml. Biochemical properties revealed that Hol6A3 retained stable activity under various conditions. Hol6A3 exhibited broad-spectrum and potent bactericidal effects against various pathogens and synergistic effects in combating bacterial infections with endolysin Ply6A3.
conclusionHol6A3 possesses considerable antibacterial potential, capable of degrading a broad spectrum of bacteria, demonstrating robust stability and a low propensity for the development of drug resistance. Consequently, Hol6A3 may emerge as a promising alternative to traditional antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.